Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPA-201 Cell Therapy in PD-(L)1 Resistant Malignant Melanoma
NCT06708455Phase 2Not yet recruiting
- Sponsor
- Rapa Therapeutics
- Start
- Mar 2027
- Primary completion
- Mar 2029
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 2 trial of rapa-201 in Malignant Melanoma (MM), sponsored by Rapa Therapeutics. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
rapa-201
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06708455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708455.